

1 **ABERRANT IMMUNE PROGRAMMING IN NEUTROPHILS IN CYSTIC FIBROSIS**

2

3

4 Yawen Hu¹, Christine M. Bojanowski², Clemente J. Britto³, Dianne Wellems¹, Kejing Song⁴,
5 Callie Scull¹, Scott Jennings¹, Jianxiong Li⁵, Jay K. Kolls⁴, Guoshun Wang^{1*}

6

7

8 ¹Department of Microbiology, Immunology and Parasitology, Louisiana State University Health
9 Sciences Center, New Orleans, Louisiana, USA

10 ²Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA

11 ³Department of Internal Medicine, Yale University School of Medicine, New Haven,
12 Connecticut, USA

13 ⁴Departments of Medicine and Pediatrics, Tulane University School of Medicine, New Orleans,
14 Louisiana, USA

15 ⁵High Performance Computing, Louisiana State University, Baton Rouge, Louisiana, USA

16

17

18

19

20

21 **Running Title:** Aberrant Transcriptional Program in CF Neutrophils

22

23

24

25 *Corresponding author:

26 Guoshun Wang, DVM, PhD

27 Department of Microbiology, Immunology and Parasitology

28 Louisiana State University Health Sciences Center

29 CSRB 607, 533 Bolivar Street,

30 New Orleans, LA 70112, U.S.A.

31 Phone: (504) 568-7908;

32 Fax: (504) 568-8500;

33 Email: gwang@lsuhsc.edu

34

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

ABSTRACT

Cystic fibrosis (CF) is a life-shortening genetic disorder, caused by mutations in the gene that encodes Cystic Fibrosis Transmembrane-conductance Regulator (CFTR), a cAMP-activated chloride and bicarbonate channel. Although multiple organ systems can be affected, CF lung disease claims the most morbidity and mortality due to chronic bacterial infection, persistent neutrophilic inflammation, and mucopurulent airway obstruction. Despite the clear predominance of neutrophils in these pathologies, how CFTR loss-of-function affects these cells *per se* remains incompletely understood. Here, we report the profiling and comparing of transcriptional signatures of peripheral blood neutrophils from CF participants and healthy human controls (HC) at the single-cell level. Circulating CF neutrophils had an aberrant basal state with significantly higher scores for activation, chemotaxis, immune signaling, and pattern recognition, suggesting that CF neutrophils in blood are prematurely primed. Such an abnormal basal state was also observed in neutrophils derived from an F508del-CF HL-60 cell line, indicating an innate characteristic of the phenotype. LPS stimulation drastically shifted the transcriptional landscape of HC circulating neutrophils towards a robust immune response, however, CF neutrophils were immune-exhausted. Moreover, CF blood neutrophils differed significantly from CF sputum neutrophils in gene programming with respect to neutrophil activation and aging, as well as inflammatory signaling, highlighting additional environmental influences on the neutrophils in CF lungs. Taken together, loss of CFTR function has intrinsic effects on neutrophil immune programming that leads to premature priming and dysregulated response to challenge.

57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79

INTRODUCTION

Cystic fibrosis (CF) is a chronic, progressive and debilitating genetic disorder, caused by mutations in the Cystic Fibrosis Transmembrane-conductance Regulator gene (*CFTR*) that encodes a cAMP-activated chloride and bicarbonate channel (1, 2). Clinically, CF affects multiple organ systems, including the lung, intestines, pancreas, liver, and reproductive system. However, the lung disease claims the most morbidity and mortality. Dominant pathological changes in the lung are chronic bacterial infection, persistent neutrophilic inflammation, and mucopurulent airway obstruction (3, 4). Highly effective *CFTR* modulator therapies can effectively correct CF epithelial defects, reflected by normalization of the sweat Cl^- transport (5, 6). However, the neutrophilic inflammation persists, suggesting a potentially different pathogenic mechanism that the current modulators are not known to target.

Polymorphonuclear neutrophils (PMN) are a major cellular component in host defense against extracellular bacterial infection, and are the first line of immune cells recruited to sites of infection and inflammation (7). The principal function of PMN is to contain, degrade and eradicate invading microorganisms through phagocytosis, cytotoxicity, and enzymatic digestion (8, 9). Once a microbial challenge is addressed, PMN are cleared by macrophages through efferocytosis to restore tissue homeostasis (10). CF lungs exhibit unrelenting neutrophilic inflammation, suggesting an abnormal immune response. However, how CF neutrophils directly contribute to this pathogenesis is not clearly known.

Single-cell RNA sequencing (scRNA-seq) is a powerful tool to infer cell behavior and function through capture and deciphering of the transcriptional dynamics of individual live cells. Previous publications have elegantly used this method to study human neutrophil heterogeneity (11), and transcriptional dynamics at different states (12). Here, we performed scRNA-seq on

80 peripheral blood neutrophils from CF participants and healthy human controls (HC) to profile
81 and compare their molecular signatures at basal state or upon challenge. CF circulating PMN
82 were also compared to CF sputum PMN to understand transcriptional reprogramming after lung
83 recruitment. Our work has demonstrated that CFTR loss-of-function in neutrophils alters the cell
84 intrinsic immune programming that is further influenced by the CF lung environment. This
85 transcriptional defect results in neutrophil premature priming and dysregulated immune response
86 to challenge.
87

88 **RESULTS**

89 **Circulating neutrophils from CF blood are abnormally primed and dysregulated in**
90 **response to LPS challenge**

91 Peripheral blood neutrophils from CF and HC subjects were isolated by Percoll density
92 gradient centrifugation (13). All the CF participants were F508del homozygotes receiving
93 Elexacaftor/Tezacaftor/Ivacaftor modulator therapy and with stable disease. Human subject
94 demographics are provided in **Supplementary Table 1**. The obtained neutrophils were divided
95 into two aliquots: one for immediate processing for scRNA-seq, and the other for culture and
96 exposure to *Pseudomonas aeruginosa* LPS for 16 hours, followed by scRNA-seq. Cell viability
97 of each condition was 90% or greater. As the cells were purified largely to a pure neutrophil
98 population, after rigorous quality control (**Supplementary Figs. 1-4**), we readily obtained
99 26,568 high-quality cells with a dataset composed of 4 experimental conditions, including 6,563
100 HC neutrophils (Neutrophils from health controls without any culture or treatment), 5,600
101 HC_LPS neutrophils (Neutrophils from health controls with culture and LPS challenge) , 7,698
102 CF neutrophils (Neutrophils from CF participants without any culture or treatment), and 6,707
103 CF_LPS neutrophils (Neutrophils from CF participants with culture and LPS challenge).
104 Uniform Manifold Approximation and Projection (UMAP) was computed of the 4 groups of
105 cells. As shown (**Fig. 1a**), HC and CF neutrophils had an overlapping UMAP distribution, while
106 LPS challenge shifted the projection pattern of the cells. Separate plotting according to genotype
107 provided a discrete view of UMAP for each genotype (**Fig. 1b & c**).

108 Similarities of differentially expressed genes (DEGs, $\text{Log}_2\text{FC} > 0.25$, $p < 0.05$) among the 4
109 groups were analyzed and are displayed in the Venn diagram (**Fig. 1d**). HC and CF neutrophils
110 shared a significant number of DEGs (53 of 122 for HC and 53 of 87 for CF). Strikingly, LPS

111 stimulation drastically changed the gene programming in both CF and HC neutrophils, reflected
112 by zero DEGs shared between HC and HC_LPS and between CF and CF_LPS. Comparison
113 between HC_LPS and CF_LPS found 127 shared items ($\text{Log}_2\text{FC} > 0.25$, $p < 0.05$) (**Fig. 1d**). The
114 top 30 DEGs from each group were profiled with immune-related genes marked (**Fig. 1e**). LPS
115 stimulation activated a different set of top DEGs (**Fig. 1e**). Gene Ontology (GO) analysis
116 revealed the top 5 predominant GO terms of each group (**Fig. 1f**). HC neutrophils showed
117 enrichment of the gene transcripts related to Negative regulation of phosphate metabolic process
118 (GO:0045936), Mononuclear cell migration (GO:0071674), Response to external stimulus
119 (GO:0032103), Respiratory chain complex (GO:0098803), and Oxidative phosphorylation
120 (GO:0006119), representing the gene signature of healthy circulating neutrophils at their basal
121 state. In contrast, neutrophils from the CF participants showed enrichment of the gene transcripts
122 related to Leukocyte proliferation (GO:0070661), Lymphocyte proliferation (GO:0046651), Cell
123 chemotaxis (GO:0060326), Regulation of innate immune response (GO:0045088), and
124 Regulation of T cell activation (GO:0050863), suggesting a status of pro-inflammatory priming.
125 Furthermore, HC neutrophils exposed to LPS upregulated the typical gene clusters related to LPS
126 response, such as Response to IL-1, Pattern recognition receptor signaling pathway, and LPS-
127 mediated signaling pathway. However, CF_LPS neutrophils differed greatly from HC_LPS
128 neutrophils with the most enhanced gene expressions related to ubiquitin protein ligase binding,
129 regulation of endopeptidase activity, and endocytic vesicle formation, indicating an aberrant
130 response to LPS (**Fig. 1f**).

131 To confirm the above findings, gene scores for immune-related properties or functions
132 were quantitatively assessed using the standard GO terms. Measurement of neutrophil activation,
133 based on 21 signature genes (*ACKR2*, *ANXA3*, *CCL5*, *CXCL8*, *CXCR2*, *CXCR4*, *F2RL1*,

134 *FCER1G, KMT2E, MYO1F, PREX1, PRG3, PRKCD, STX11, STXBP2, STXBP3, SYK, TYROBP,*
135 *VAMP2, VAMP7, and VAMP8*) (GO: 0042119), indicated that CF neutrophils in circulation had a
136 significantly higher activation score than HC neutrophils, verifying that these cells in their basal
137 state had been primed for pro-inflammatory response. Surprisingly, under LPS stimulation CF
138 blood neutrophils had a significantly lower activation score than HC neutrophils (**Fig. 2a**),
139 indicating a blunted immune response. These findings were further confirmed by significantly
140 higher scores of CF neutrophils for Chemotaxis (GO:0030593) and Cytokine-related signaling
141 (GO:0019221) at their basal state in circulation, but significantly lower scores of these immune
142 properties upon LPS challenge (**Fig. 2b & c**). Moreover, CF neutrophils also had significantly
143 lower scores for Neutrophil migration (GO:1990266) and Immune response-regulating signaling
144 (GO:0002764) under LPS stimulation (**Fig. 2d & e**). Furthermore, the scores of specific
145 signaling pathways that are highly related to neutrophil innate immune functions were also
146 calculated. Toll-like receptor signaling (GO:0002224), Pattern recognition receptor signaling
147 (GO:0002221), and LPS response signaling (GO:0032496) in CF circulating neutrophils had
148 significantly higher scores than those in HC circulating neutrophils at their basal state (**Fig. 2f -**
149 **h**), but with LPS challenge these signaling pathways were significantly down-regulated (**Fig. 2f -**
150 **h**). All these data support the conclusion that CF blood neutrophils are abnormally primed at
151 their basal state, and subdued in response to challenge.

152 To rule out the possibility that the observed transcriptomic difference between HC and
153 CF neutrophils was derived from different cell isolation methods or subject disparities, we
154 compared our dataset with that of selected cohorts from the published dataset by Franco Lab
155 (14), for which their neutrophils were isolated by negative selection (**Supplementary Table 1**).
156 Results indicated that the 2 HC datasets integrated well in a good overlapping UMAP (**Fig. 2i**).

157 Three-group comparisons demonstrated that the neutrophil activation score and cytokine-
158 mediated signaling pathway score of the CF circulating neutrophils were significantly higher
159 than those of Franco Lab HC cohorts, validating the results from comparing with our HC cohorts
160 (**Fig. 2 j & k**). Thus, circulating neutrophils in CF blood indeed have an aberrant immune
161 transcriptional program at their basal state.

162

163 **CF and healthy neutrophils show differential state transition upon LPS challenge**

164 Normal neutrophils upon challenge undergo a programmed transformation from basal
165 state to activating state, and further to aging state. Monocle trajectory of our HC data revealed
166 such three states (**Fig. 3a**), which correlated well with experimental conditions (with or without
167 LPS) (**Fig. 3b**). Specifically, basal state HC cells were from the non-LPS group, while the cells
168 in activating and aging states were predominantly from the LPS-treated group. Intriguingly, LPS
169 stimulation resulted in two distinct subpopulations, showing a bifurcation in trajectory (**Fig. 3b**).
170 Cells at the three states from the HC cohorts were color-mapped in UMAP (**Fig. 3c**). GO
171 analysis was conducted to define the gene signature of each state. The basal state HC neutrophils
172 highly enriched the transcripts related to Actin filament organization, Negative regulation of
173 phosphate metabolic process, and Leukocyte cell adhesion (**Fig. 3d**). Despite the fact that the
174 activating state and aging state were all derived from LPS stimulation, they differed in their top
175 GO enrichment. The gene clusters that were uniquely or significantly enriched at activating state
176 were highly immune-related, and included Chemokine-mediated signaling, Proton
177 transmembrane transport, Granulocyte migration, and Wound healing. In contrast, the top GO
178 terms for the HC neutrophils at aging state were related to Negative regulation of endopeptidase
179 activity, Negative regulation of proteolysis, Positive regulation of cell adhesion, Regulation of

180 inflammatory responses, and Intrinsic apoptotic signaling, suggesting that the cells were
181 progressing from an immune-active state to an immune-aging state and towards programmed cell
182 death. CF neutrophils were found to share the general pattern in trajectories (**Fig. 3e & f**) with
183 the HC neutrophils (**Fig. 3a & b**). Color-mapped UMAP for each state of the CF cohorts (**Fig.**
184 **3g**) showed a similar projection pattern as the HC cohorts (**Fig. 3c**). Composition analyses of the
185 HC_LPS and CF_LPS cells demonstrated that the majority (~66%) of HC_LPS cells were at
186 activating state, while the remaining ~33% cells at aging state (**Fig. 3h**). In contrast, CF_LPS
187 population at activating state occupied ~37%, while the majority (~62%) were at aging state
188 (**Fig. 3h**). This result suggests that the majority of CF_LPS neutrophils were already further
189 along in the aging/cell death trajectory. Similarity comparisons of DEGs of HC_LPS and
190 CF_LPS neutrophils at either activating state or aging state revealed over 50% of shared DEGs at
191 each state. However, there were a significant number of DEGs that were not shared between
192 genotypes (**Fig. 3i & j**).

193

194 **CF and healthy neutrophils display differential cell-fate decision and cell-aging processes** 195 **after LPS challenge**

196 RNA velocity analysis is an effective method to predict cell-fate commitment and cell-
197 aging processes using the information from newly transcribed pre-mRNAs (unspliced) and
198 mature mRNAs (spliced) (15). Velocities derived from the dynamic models of HC and CF
199 neutrophils were visualized as streamlines in their corresponding UMAP-based embedding,
200 revealing the standing of each cell in their life journey and fate direction (**Fig. 4a & c**). Each
201 arrow represented a velocity vector indicating the predicted direction and speed of progression
202 along the direction of an individual cell. There were two starting points at the basal state for HC

203 or CF, as circled (**Fig. 4a & c**), which correlated well with the root cells identified by
204 terminal_states analysis (**Fig. 4b & d**). Upon LPS challenge, the majority of basal state HC
205 neutrophils took the direction towards the aging state, the end point of their life journey (**Fig.**
206 **4c**). HC neutrophils in the activating state also pointed to the aging state. However, CF
207 neutrophils had a strong velocity pattern that originated from the basal state, headed toward the
208 aging state, and ended in the activating state (**Fig. 4c**). Such an unusual senile activation reflects
209 an ill-selected fate and ill-programmed cell death, which could lead to a protracted inflammation.

210 To better define the gene signature of the activating or the aging states and to determine
211 how CFTR mutation alters the gene enrichment in each state, the top 10 up-regulated and the top
212 10 down-regulated genes in CF neutrophils from comparison with the HC counterparts were
213 inspected and are displayed in the heatmap (**Fig. 4e**). In the activating state, the most upregulated
214 genes in CF neutrophils were related to regulating lysosomal functions (e.g. *GRN* and *LAPTM5*)
215 and neutrophil development and survival (e.g. *NAMPT* and *CEBPB*), while the most down-
216 regulated genes in CF neutrophils included acute phase protein gene (e.g. *ORM1*), CD45 coding
217 gene *PTPRC*, and MHC I alpha chain coding gene *B2M* (**Fig. 4e**), which were associated with
218 significantly lower scores for cell activation, chemotaxis, and reactive oxygen species (ROS)
219 (**Fig. 4f**). Hence, while they had an early pro-inflammatory priming, the CF neutrophils upon
220 challenge seemed to be immune-exhausted, reflected by significantly weakened immune
221 activation and response. GO enrichment analysis also supported this conclusion by showing that
222 CF neutrophils in the activating state enriched the transcripts related to Cell-substrate junction
223 (GO:0030055), Focal adhesion (GO:0005925) and Epithelial cell migration (GO:0010631),
224 which were not directly involved in neutrophil immune function (**Supplementary Fig. 5**). As for
225 the aging state, the most upregulated genes in CF neutrophils included *FCGR3B*, *CXCR2*, *HLA-*

226 *A*, and *SDCBP*, and the most downregulated genes where *S100A12*, *TIMP1*, and *C15orf48* (**Fig.**
227 **4e**). These regulations were associated with significantly higher scores for differentiation, aging,
228 apoptosis, and necrosis, as compared to HC neutrophils in the same state (**Fig. 4g**). Because
229 neutrophil immune function is highly associated with phagosomal function(16), we then
230 examined the scores for granule formation (azurophil, specific, tertiary and secretory). These
231 analyses showed that CF neutrophils in their activating state had a higher azurophil granule score
232 but a lower secretory score, but in the aging state, the CF neutrophils had a significantly higher
233 scores for azurophil, specific and tertiary granules (**Fig. 4h**). As granule proteins are normally
234 pre-synthesized during neutrophil maturation(17), re-activation of these granule genes in the
235 aging state confirmed a dysregulated gene programming for phagosomal function. These data
236 indicate that CF neutrophils have irregular cell-fate decision and disordered cell activation and
237 ending programs, which likely compromises their function and clearance.

238

239 **Neutrophils derived F508del-CF HL-60 cell line have a pro-inflammatory basal state and** 240 **abnormal immune response to LPS**

241 The identified pro-inflammatory basal state of CF circulating neutrophils can be
242 determined by intrinsic neutrophil properties or induced by blood environmental factors. To
243 explore this issue, we measured the levels of endotoxin and key pro-inflammatory cytokines (IL-
244 8, IL-6, TNF- α and IL-1 β) in the plasma samples of HC and CF subjects. All the measured
245 samples had no detectable levels of the cytokines, and only one HC plasma had a very low level
246 of endotoxin (~0.07 U/ml) (**Supplementary Fig. 6**). These data led us to speculate that the
247 aberrant transcriptional program in CF neutrophils is likely intrinsic. To further explore this
248 possibility, we differentiated WT HL-60 cells (18) and F508del-CF HL-60 cells (19) with 1.25%

249 DMSO into their corresponding neutrophil-like cells. ScRNA-seq was similarly performed and
250 the gene signatures of these derived neutrophils with or without LPS stimulation were compared.
251 There were 4 groups of samples: 1) WT_dHL-60 (WT neutrophils differentiated from wild-type
252 HL-60 cell line), 2) CF_dHL-60 (CF neutrophils differentiated from F508del-CF HL-60 cell
253 line), 3) WT_dHL-60_LPS (WT_dHL-60 stimulated with LPS), and 4) CF_dHL-60_LPS
254 (CF_dHL-60 stimulated with LPS). UMAP for each genotype of cells was separately plotted,
255 showing a comparable projection pattern (**Fig. 5a & b**). Top 5 GO enrichments indicated that
256 WT_dHL-60 neutrophils largely enriched the transcripts related to immune cell development,
257 while CF_dHL-60 cells most enriched those related to regulation of innate immune responses
258 and granule formation (**Fig. 5c**), reflecting a pro-inflammatory priming. Upon LPS challenge,
259 WT_dHL-60 neutrophils upregulated genes related to a typical immune response to LPS, such as
260 Cytokine activity, Neutrophil chemotaxis, Neutrophil migration, Response to tumor necrosis
261 factor, and LPS-mediated signaling pathway, while CF_dHL-60 cells failed in this response, and
262 turned to antioxidant activity, collagen catabolic process, and antigen processing and
263 presentation (**Fig. 5c**). Moreover, CF_dHL-60 neutrophils without LPS stimulation had a
264 significantly higher neutrophil activation score (GO: 0042119) (**Fig. 5d**), and significantly
265 upregulated the hallmark gene sets responsible for neutrophil immune functions (**Fig. 5h-k**).
266 With LPS stimulation, CF_dHL-60 neutrophils had significantly lower scores for the immune
267 features than WT_dHL-60 counterparts (**Fig. 5e-k**). These results corroborate the findings from
268 the CF circulating neutrophils that CFTR mutation renders neutrophils pro-inflammatory in basal
269 state and dysregulated in response to LPS challenge.

270

271 **CF lung environment further affects CF neutrophil gene programming**

272 CF neutrophils mobilized to CF lungs have to go through extravasation, migration,
273 adaptation, activation, cell death and clearance. To discern any differences in gene programming
274 between circulating and airway neutrophils in CF, we compared our CF blood neutrophil dataset
275 with a published one of CF sputum neutrophils (20). To match our CF patients' demographic
276 characteristics and treatments, only homozygous F508del CF subjects under similar modulator
277 therapy were selected (**Supplementary Table 1**). Integration of the datasets gave rise to an
278 overall UMAP showing 3 distinct cell congregations with unique DEG profiles (**Fig. 6a & b**).
279 While a small proportion of CF sputum PMN overlapped with CF blood PMN and CF blood
280 PMN_LPS, CF sputum PMN showed large differences in gene expression (**Fig. 6a & b**). MHC I
281 related genes (*MATP1*), oxidative stress related genes (*OXSRI*), and aldehyde dehydrogenase
282 coding gene *ALDH1A2* were highly expressed in CF sputum PMN (**Fig. 6b**). GO analysis of
283 DEGs revealed that CF sputum PMN shared few GO terms with CF blood neutrophils,
284 suggesting that the CF lung environment imposed significant influences on neutrophil gene
285 programming (**Fig. 6c**). Notably, genes involved in GTPase activity (*ARHGAP15*, *GAB2*),
286 GTPase activation (*DOCK4*), and proteolysis were on the top GO list from CF sputum PMN.
287 GTPases are known to function as molecular switches to shut down activation(21). Increase in
288 neutrophil proteolysis activity in the lung may cause substantial lung damage. Furthermore,
289 KEGG pathway analysis revealed that CF sputum PMN shared some but not all pathways with
290 CF blood PMN_LPS, including Chemokine signaling pathway, Lipid and atherosclerosis, and
291 NF- κ B signaling pathway (**Fig. 6d**).

292 CF sputum PMN had the lowest differentiation score and highest aging, apoptosis, and
293 necrosis scores (**Fig. 7a**), suggesting that the sputum PMN were in a disordered state leading to
294 incongruent cell activation, survival, and host defense programs. While the cells were less aging

295 relative to circulating PMN, they expressed increased apoptosis- and necrosis-associated genes,
296 when compared with CF blood PMN_LPS samples. CF sputum PMN had significantly lower
297 scores for azurophil, tertiary and secretory granule gene sets, but a significantly higher score for
298 specific granule gene set, as compared to those of CF blood PMN_LPS samples (**Fig. 7b**).
299 Moreover, the scores for ROS pathway, Migration and Chemotaxis showed a substantial
300 reduction in CF sputum PMN (**Fig. 7c**). Conversely, the score for Phagocytosis was significantly
301 higher in CF sputum PMN (**Fig. 7c**). Furthermore, the gene sets for Inflammatory response, IL6-
302 JAK-STAT3 signaling, TGF β signaling, and TNF α -NF κ B signaling were significantly
303 upregulated in CF sputum PMN (**Fig. 7d**). These comparisons clearly indicated that the immune
304 program in CF sputum neutrophils further deviated from the altered in the CF circulating
305 neutrophils. Taken together, CF sputum neutrophils had a severely disordered transcriptional
306 programming that could delay their maturation, exacerbate immune dysfunction and accelerate
307 necrotic cell death. These data provide one molecular explanation to how CF lungs are inflicted
308 by persistent neutrophilic inflammation and purulent airway obstructions.

309

310

311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332

Discussion

Persistent neutrophilic inflammation is a major pathogenic factor in CF that damages organ structure and function. However, the mechanism underlying the pathogenesis has not been clearly defined. The current report provides comprehensive data demonstrating that CF neutrophils have intrinsic anomalies in immune programming. Notably, peripheral blood neutrophils from CF patients exhibited pro-inflammatory priming before recruitment to any target organs. Such dysregulated and premature activation led to an exaggerated but dysregulated immune response at the transcriptional level. Of note, our CF subjects were all under the Elexacaftor/Tezacaftor/Ivacaftor modulator therapy. Such observed abnormalities suggest that the current CFTR modulators may not be effective in rectifying CF neutrophil innate immune defects.

An early microarray analysis revealed that peripheral blood neutrophils from CF patients upregulate their pro-inflammatory genes, including *G-CSF*, *CXCL10*, *CCL17*, *IKK ϵ* , and *IL-10Ra* (22), which is consistent with our finding that CF circulating neutrophils are pre-primed. Schupp and colleagues performed scRNA-seq of neutrophils isolated from the sputum of CF patients, and found a prevalence of immature pro-inflammatory neutrophils(20). Direct comparison of their CF sputum neutrophil data with our CF blood neutrophil data has revealed significant transcriptional re-programming, which amplified the innate abnormality of CF circulating neutrophils. These data have confirmed a recently published bulk-RNA-seq study that demonstrated that CF neutrophils, after migrating through an air-liquid interface culture of H441-cell-derived airway epithelia, undergo extensive transcriptional transformations related to immune response genes (23).

333 Numerous previous reports have documented CF PMN dysfunction phenotypically,
334 including suboptimal activation (24), cleavage of CXCR1 (25), hyper-sensitivity to LPS
335 stimulation (26), irregular or deficient production of reactive oxygen species (27, 28), alteration
336 in inflammatory signaling (29), hyper-production of IL-8 (30, 31) , abnormal extracellular trap
337 formation (32), hyper-oxidation of glutathione (33), dysregulation of protease secretion and
338 degranulation, delayed apoptosis (34), and abnormal granule release (35). Moreover, CF blood
339 neutrophils express higher levels of CD64, a marker of neutrophil activation, and lower levels of
340 Toll-like receptor-2 (TLR2) compared with healthy blood neutrophils. Further, TLR2, TLR4 and
341 IL-8 expression in CF airway neutrophils was higher than in CF blood neutrophils (36). As cell
342 phenotype is at least in part determined by gene activities, these phenotypic abnormalities reflect
343 gene programming anomalies in CF neutrophils. Our current scRNA-seq data will be valuable in
344 understanding the molecular basis of these functional defects.

345 In this report, three tiers of comparisons of neutrophil transcriptomes were performed: 1)
346 inter-genotype comparison (HC vs CF); 2) inter-state comparison (basal state vs activating state
347 vs aging state) of each genotype; and 3) inter-compartment comparison (blood vs sputum). The
348 inter-genotype comparison allowed us to discern the differences in gene programming between
349 genotypes. We found that HC and CF neutrophils shared many core expressing genes (**Fig. 1d**),
350 but CF neutrophils in the blood were innately primed (**Fig. 1f & 2a**). Such a premature activation
351 is independent of external inductions by pro-inflammatory cytokines or endotoxin. More
352 importantly, despite the early start in activation CF neutrophils failed to organize an effective
353 immune response to LPS at the transcriptional level.

354 The inter-state comparison uncovered how CF and HC neutrophils responded to LPS
355 challenge differently. We found that CF neutrophils differed from HC neutrophils in their fate

356 decision and aging/death processes. Instead of natural aging and apoptosis in HC neutrophils, CF
357 neutrophils manifested a senile activation. This abnormal aging process might lead to a
358 prolonged state of neutrophilic inflammation. Moreover, CF neutrophils had a significantly
359 higher necrosis score in either activating or aging state (**Fig. 4g**), and a significantly higher
360 combined necrosis score of both states (**Supplementary Fig. 7**). Necrosis is a cell autolysis that
361 does not follow the apoptotic signaling pathway, from which uncontrolled release of products of
362 cell death into the extracellular space provokes strong inflammatory response (37). The high
363 necrosis score of CF neutrophils upon LPS challenge may underlie a mechanism for purulent
364 inflammation observed in CF lungs.

365 The inter-compartment comparison revealed that CF sputum neutrophils had significantly
366 less enrichment of gene transcripts related to azurophil and tertiary granule formation and ROS
367 production, when compared with LPS-stimulated CF circulating neutrophils. Neutrophil granules
368 play an essential role in neutrophil innate immune function. Four types of granules are produced
369 during neutrophil development and maturation (11). Primary granules are formed at the earliest
370 stage of neutrophil differentiation in the bone marrow, and contain potent proteases, such as
371 neutrophil elastase (NE), cathepsin G, the chlorinating enzyme myeloperoxidase (MPO) and
372 antimicrobial agents such as defensins (38). Although LPS stimulation upregulates the different
373 granule genes in healthy neutrophils (11), which was also proved in our data (**Supplementary**
374 **Fig. 7**), CF blood neutrophils under LPS challenge had even higher expression of these genes
375 (**Fig. 4h**). Our analyses have also shown that CF sputum neutrophils had significantly higher
376 granule scores even than the LPS-challenged CF blood neutrophils (**Fig. 7b**), suggesting that CF
377 lungs may have more abundant or stronger agonists to stimulate the lung-recruited neutrophils.
378 Primary granules generally fuse with the phagosome for bacterial killing to avoid tissue damage

379 (38, 39), but uncontrolled degranulation of CF neutrophils does not serve anti-microbial
380 function, instead produces bystander tissue damage (23). Large amounts of NE and MPO have
381 been found in the airway at a very early life stage of CF patients (40). NE burden in the airway
382 accelerated the cleavage of CXCR1, resulting in poor bacterial killing but persistent
383 inflammation. NE activity is negatively correlated with lung function in CF patients (41). Thus,
384 an unbalanced production of granules would interfere with optimal phagosomal function and
385 effective lung defense.

386 Human neutrophils pre-synthesize CFTR that is pre-stored in the secretory vesicle
387 membrane (28). When integrated into the phagosomal membrane, CFTR serves as a major
388 chloride channel to transport chloride to the organelle (42). CFTR is crucial to regulating
389 phagosomal functions, including charge balance, pH maintenance and oxidant production (43-
390 45). Our previous work and others' have demonstrated that CFTR loss of function in CF
391 neutrophils results in a deficit in chloride supply to the phagosomes, leading to deficiency in
392 microbial killing and resolution of inflammation (42, 46, 47). In addition to the phagosomal
393 chloride supply and oxidant production defect, CF neutrophils have aberrant gene programming,
394 which may further undermine neutrophil innate immune function.

395 In summary, our study has provided critical data demonstrating that CF neutrophils are
396 intrinsically pro-inflammatory. Such an innate anomaly is determined by internal gene
397 programming, which renders the cells hyper-responsive to stimulation, and less effective in host
398 defense function. This finding helps explain at the gene level why CF lungs have unremitting
399 neutrophilic inflammation that causes long-term tissue damage and accelerated lung functional
400 decline in CF.

401 This study has several limitations: First, the sample sizes of CF and HC cohorts were
402 relatively small. As we only targeted the single neutrophil population, deep sequencing of
403 enough high-quality cells was readily achieved. However, only 3 CF and 3 HC subjects were
404 recruited to this study. Second, this is a single center investigation. Although published datasets
405 of CF and HC subjects from other centers were mined and compared with ours, our own
406 sequencing data were from the participants from a single CF care center. Third, all the recruited
407 CF patients were homozygous in F508del CFTR gene mutation, and had been receiving the ETI
408 modulator therapy. Patients with other CFTR mutations and receiving no modulator treatments
409 were not covered in this study.

410 MATERIALS AND METHODS

411 Human study ethical statement

412 This study involved human blood samples. The experimental design was approved by the
413 Institutional Review Boards of Tulane University Health Sciences Center and Louisiana State
414 University Health Sciences Center, Louisiana State, USA. Informed consent from each
415 participant was obtained before any sample collection.

416

417 Human neutrophil isolation and processing

418 Peripheral blood (10 cc) from 3 CF patient and 3 healthy donors (**Supplementary Table**
419 **1**) were drawn into a BD Vacutainer® Blood Collection Tube (EDTA K2). The selected patients
420 were homozygous for the F508del variant or $\Delta F508$) with stable mild to moderate lung disease.
421 Lung disease stability was clinically defined as demonstrating no recent change in lung function
422 and without clinical signs of acute bronchiectasis exacerbation. All 3 CF participants were being
423 treated with the CFTR protein modulators: elexacaftor/texacaftor/ivacaftor (ETI). After Percoll-
424 gradient centrifugation (65%/75%), the neutrophil layer of each sample was collected and
425 resuspended in pre-cooled RPMI-1640 (Gibco) medium without any supplements. The obtained
426 cells were divided into two aliquots: one immediately processed for scRNA-seq, and the other
427 cultured in complete RPMI-1640 media supplemented with 2 mM GlutaMax (Gibco), 10% heat-
428 inactivated bovine growth serum (Hyclone), 100 U/ml penicillin (Gibco), 100 $\mu\text{g}/\text{ml}$
429 streptomycin (Gibco) and 0.25 $\mu\text{g}/\text{ml}$ amphotericin B (Sigma), and stimulated with *P.*
430 *aeruginosa* LPS (Sigma; 40 $\mu\text{g}/\text{mL}$) for 16 hours, followed by scRNA-seq.

431

432 Cell hashing, library construction and sequencing

433 In order to minimize sample to sample variations, hashtag oligonucleotides (HTO)
434 against human β 2-microglobulin (β 2M) were used to tag different groups of cells. Three samples
435 from blood donors in each group were tagged with following hashtag oligonucleotides:
436 TotalSeq™-B0251 anti-human Hashtag 1 Antibody (BioLegend Cat. No. 394601), TotalSeq™-
437 B0252 anti-human Hashtag 2 Antibody (BioLegend Cat. No. 394603); TotalSeq™-B0253 anti-
438 human Hashtag 3 Antibody (BioLegend Cat. No. 394605). Cells were loaded onto the 10X
439 Chromium controller, and cell viability was evaluated by Cellometer (Nexcelom Bioscience)
440 with AO/PI staining. Five thousand neutrophils from each donor were targeted. The libraries
441 were prepared using Chromium Single Cell 3' v3.1 protocol (10x Genomics). Cellular mRNA
442 and antibody-derived oligos were reverse-transcribed and indexed with a shared cellular barcode.
443 The mRNA derived cDNA and antibody-derived tagged DNA were constructed to libraries
444 according to the Chromium Single Cell 3' v3.1 protocol (10x Genomics). The mRNA derived
445 cDNA library and antibody-derived tagged library were pooled and sequenced at 4:1 ratio with
446 paired-end reads on an Illumina NextSeq 2000 (Illumina).

447

448 **HL-60 cell culture and neutrophil differentiation**

449 A homozygous F508del-CF HL-60 cell line (CF_HL-60)(48) and the parental wild-type
450 HL-60 cell line (WT_HL-60) were cultured in RPMI-1640 (Gibco) supplemented with 2 mM
451 GlutaMax (Gibco), 10% heat-inactivated bovine growth serum (Hyclone), 100 U/ml penicillin
452 (Gibco), 100 μ g/ml streptomycin (Gibco) and 0.25 μ g/ml amphotericin B (Sigma). To
453 differentiate the cells into neutrophils, 1.25% of DMSO (Sigma-Aldrich) was added to the
454 medium for 5 days with medium replenishment at Day 3. The differentiated neutrophils were

455 submitted for scRNA-seq using the same procedure as for the human blood neutrophils described
456 above.

457

458 **ScRNA-seq data processing**

459 Primary analyses were performed using 10x Cellranger V.6.1.2, including alignment of
460 the sequencing reads to the GRCh38-2020-A human transcriptome, and quantification of
461 transcript expressions in each cell. The downstream quality control and data analyses were
462 achieved using R version 4.1.3 and the package Seurat version 4.2.1(49) except where otherwise
463 noted.

464

465 *Seurat data QC and demultiplex*

466 The output folder from Cell Ranger 6.1.2, containing barcodes, features, and matrix, was
467 loaded into R by the Read10X() function from Seurat. For quality control, cells that have
468 mitochondrial gene counts lower than 5% with unique feature counts more than 150 and less
469 than 2500 (subset = percent.mt < 5 & nFeature_RNA>150 & nFeature_RNA<2500)), were
470 accepted for downstream analysis. All the qualified cells were demultiplexed using the
471 HTODemux() function, according to their HTO barcode. Doublet and negative cells were ruled
472 out.

473

474 *Dimension reduction and unsupervised clustering*

475 After removing unwanted (low quality) cells, the dataset was normalized by the
476 NormalizeData() function, and scaled by the SCTransform() function with *method* =
477 "glmGamPoi", *vars.to.regress* = "percent.mt". The first 30 principal components (PCs) were

478 used to compute a Uniform Manifold Approximation and Projection (UMAP) embedding of the
479 cells with the functions: FindNeighbors(), RunUMAP(), and FindClusters(). The states of
480 neutrophils were identified by Monocle2 2.24.1(50) using the reduceDimension() function. To
481 integrate datasets and eliminate the batch-batch difference between each dataset, R package
482 Harmony 0.1.0 was used for batch correction (51).

483

484 *Identification of differentially expressed genes (DEGs) and analysis of gene ontology (GO)*

485 Differentially expressed genes of each cluster or group were identified by function
486 FindMarkers() or FindAllMarkers() with adjusted P value < 0.05 and $\log_2FC > 0.5$. Bonferroni
487 correction was performed to adjust P value. The lists of DEGs were also used for GO analysis
488 and KEGG pathway analysis by using the R package ClusterProfiler 4.2.2 (52).

489

490 *RNA velocity analysis*

491 RNA velocity analysis was performed using velocity.py 0.17.16 (15) command-line
492 tools to convert bam files to loom files. Then, the downstream analysis was performed by scVelo
493 0.2.5 pipeline (53) to estimate RNA velocity at dynamic states (scv.tl.recover_dynamics). We
494 used Seurat cells embedding to show the RNA velocity, root cells, and end point of the
495 underlying cellular processes.

496

497 *Scoring of biological process and pathway activity*

498 Individual cells were scored for their expression of gene signatures representing certain
499 biological functions and pathway activities. Each functional signature gene set was derived from
500 the Molecular Signatures Database (MSigDB), including hallmark gene sets (54) and the Gene

501 Ontology gene sets. Neutrophil function related scores (GO: 0042119; 0030593; 0019221;
502 1990266; 0002764; 0002224; 0002221; 0032496) were calculated by the AddModuleScore ()
503 function with DEGs enriched in corresponding GO terms. All other signature functional scores
504 reflecting certain gene set activity were calculated by R package: AUCell 1.18.1 (55) with the
505 AUCell_buildRankings() function to compute gene expression rankings in each cell and the
506 AUCell_calcAUC() function to calculate area-under-the-curve (AUC) values of each gene set in
507 a cell. AUC values represent the fraction of genes within the top-ranking genes for each cell that
508 are defined as part of the pathway gene set (56).

509

510 **Cytokine and endotoxin measurements**

511 R&D Systems DuoSet ELISAs were used to assess TNF- α , IL-8, IL-6, and IL-1 β levels
512 in healthy control plasma samples and CF patient plasma samples according to the manufacturer
513 protocol with freshly made buffers and diluents. In brief, plates were coated overnight with
514 capture antibody reconstituted in PBS (Gibco). Plates were washed and blocked for 2 hours.
515 Standards and samples were then prepared and diluted in proper diluents as recommended by the
516 manufacturer and incubated at room temperature for 2 hours. Plates were washed with 0.05%
517 Tween-20 (Thermo Fisher) in PBS. Detection antibody reconstituted in appropriate reagent
518 diluent as per manufacturer protocol was added to samples and standards and incubated at room
519 temperature for 2 hours. Plates were washed again. Working dilutions of Streptavidin-HRP
520 (R&D Systems) were added to each well and incubated in the dark for 20 min. Plates were
521 washed and substrate solution (Thermo Scientific Ref: 34028) was added to each well and plates
522 were incubated in the dark for 20 min. Stop solution (2N H₂SO₄) was added to each well and

523 plates were measured at 540 nm and 450 nm. Wavelength correction was performed by
524 subtracting readings at 540 nm from readings at 450 nm.

525 For endotoxin measurement, the Pierce Chromogenic Endotoxin Quant Kit (Thermo
526 Scientific Cat: A39552) was used to determine endotoxin levels in healthy human and CF patient
527 plasma samples according to the manufacturer instructions. All reagents were pre-warmed and
528 kept at 37°C using a plate warmer. In brief, endotoxin standards were made by reconstituting
529 lyophilized endotoxin with endotoxin free water. Standards with low concentrations (0.01-0.1
530 EU/mL) were made according to the recommended protocol. Plasma samples were diluted 50
531 fold in endotoxin free water per protocol suggestion. Standards and samples were added to each
532 well prior to addition of reconstituted Amebocyte Lysate Reagent. Samples were incubated at
533 37°C for 20 min (time directed as T1 for Low standard time). Reconstituted chromogenic
534 substrate solution was added to each well and incubated at 37°C for 6 min. Stop solution (25%
535 acetic acid) was added to each well and the plate was read at 405 nm. To validate the
536 measurement, randomly selected plasma samples were spiked with a known amount of LPS, and
537 measured in parallel.

538

539 **Statistical analyses**

540 A two-tailed, unpaired Student's t-test was used for 2 group comparisons. For one factor,
541 more than 2 group comparisons, one-way ANOVA was performed. For 2 factors comparisons,
542 two-way ANOVA was performed. The values shown in each figure are represented as mean \pm
543 SD. $P < 0.05$ was considered statistically significant (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). All
544 statistical analyses and graphics were made using GraphPad Prism 9, SigmaStat (SyStat
545 Software, San Jose, CA), or R 4.1.3 (package: ggplot2 3.3.6).

546

547 **Data availability**

548 All scRNA-seq data have been deposited in the Gene Expression Omnibus (GEO)
549 database. The human blood neutrophil data (CF patients and healthy controls) are under the
550 accession code GSE220658, and the HL-60-derived neutrophil data are under the accession code
551 GSE220913. This study has also mined other investigators' published datasets: 1) the healthy
552 control blood neutrophil data from the Franco Lab (14) are under the accession code
553 GSE188288, and the CF sputum neutrophil data from Britto Lab (20) are under the accession
554 code GSE145360. All the used subjects from the two published datasets were selected to match
555 the criteria of our human subjects.

556

557 **Code availability**

558 No custom software was used in this study. Methods described all the used analytical
559 tools. R code is available from the corresponding author upon request.

560

561 **Acknowledgments**

562 The authors would like to thank Dr. William M. Nauseef at University of Iowa for his
563 advice on this project. This work was supported by grants to GW from The National Institutes of
564 Health (HL150370) and The Cystic Fibrosis Foundation (WANG18I0) and by the Gilead
565 Research Scholar Program in Cystic Fibrosis to CMB. Portions of this research were conducted
566 with high performance computational resources provided by the Louisiana Optical Network
567 Infrastructure (<http://www.loni.org>).

568

569 **Author contributions**

570 YH, DW, KS, CS and SC performed the experiments; CMB did clinical evaluation,
571 subject selection and consent, and blood sample collection; KS and JKK performed the single-
572 cell RNA sequencing and primary data analyses. YH, JL and CJB carried out the secondary data
573 analyses.

574

575 **Competing interests**

576 The authors declare no competing interests.

577

578

579 **References:**

580

- 581 1. Ramsey BW, Welsh MJ. AJRCCM: 100-Year Anniversary. Progress along the Pathway of
582 Discovery Leading to Treatment and Cure of Cystic Fibrosis. *Am J Respir Crit Care Med*
583 2017; 195: 1092-1099.
- 584 2. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole
585 JL, Kennedy D, Hidaka N, et al. Identification of the cystic fibrosis gene: chromosome
586 walking and jumping. *Science* 1989; 245: 1059-1065.
- 587 3. Davis PB. Cystic fibrosis. *Pediatr Rev* 2001; 22: 257-264.
- 588 4. Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. *N Engl J Med*
589 2015; 372: 1574-1575.
- 590 5. Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond
591 D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD,
592 Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van
593 Dalfsen JM, Kloster MH, Rowe SM, group PS. Clinical Effectiveness of
594 Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. *Am J*
595 *Respir Crit Care Med* 2022; 205: 529-539.
- 596 6. Griese M, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS,
597 Ringshausen FC, Taylor-Cousar JL, Withers NJ, Moskowitz SM, Daines CL. Safety and
598 Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with
599 Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label
600 Phase 3 Clinical Trial. *Am J Respir Crit Care Med* 2021; 203: 381-385.
- 601 7. Nauseef WM, Borregaard N. Neutrophils at work. *Nat Immunol* 2014; 15: 602-611.
- 602 8. Klebanoff SJ, Kettle AJ, Rosen H, Winterbourn CC, Nauseef WM. Myeloperoxidase: a front-
603 line defender against phagocytosed microorganisms. *J Leukoc Biol* 2013; 93: 185-198.
- 604 9. Winterbourn CC, Kettle AJ, Hampton MB. Reactive Oxygen Species and Neutrophil
605 Function. *Annu Rev Biochem* 2016; 85: 765-792.
- 606 10. Doran AC, Yurdagul A, Jr., Tabas I. Efferocytosis in health and disease. *Nat Rev Immunol*
607 2020; 20: 254-267.
- 608 11. Xie X, Shi Q, Wu P, Zhang X, Kambara H, Su J, Yu H, Park SY, Guo R, Ren Q, Zhang S,
609 Xu Y, Silberstein LE, Cheng T, Ma F, Li C, Luo HR. Single-cell transcriptome profiling
610 reveals neutrophil heterogeneity in homeostasis and infection. *Nat Immunol* 2020; 21:
611 1119-1133.
- 612 12. Montaldo E, Lusito E, Bianchessi V, Caronni N, Scala S, Basso-Ricci L, Cantaffa C,
613 Masserdotti A, Barilaro M, Barresi S, Genua M, Vittoria FM, Barbiera G, Lazarevic D,
614 Messina C, Xue E, Markt S, Tresoldi C, Milani R, Ronchi P, Gattillo S, Santoleri L, Di
615 Micco R, Ditadi A, Belfiori G, Aleotti F, Naldini MM, Gentner B, Gardiman E, Tamassia
616 N, Cassatella MA, Hidalgo A, Kwok I, Ng LG, Crippa S, Falconi M, Pettinella F, Scapini
617 P, Naldini L, Ciceri F, Aiuti A, Ostuni R. Cellular and transcriptional dynamics of human
618 neutrophils at steady state and upon stress. *Nat Immunol* 2022; 23: 1470-1483.
- 619 13. Kuhns DB, Priel DAL, Chu J, Zarembek KA. Isolation and Functional Analysis of Human
620 Neutrophils. *Curr Protoc Immunol* 2015; 111: 7 23 21-27 23 16.
- 621 14. Wigerblad G, Cao Q, Brooks S, Naz F, Gadkari M, Jiang K, Gupta S, O'Neil L, Dell'Orso S,
622 Kaplan MJ, Franco LM. Single-Cell Analysis Reveals the Range of Transcriptional
623 States of Circulating Human Neutrophils. *J Immunol* 2022.

- 624 15. La Manno G, Soldatov R, Zeisel A, Braun E, Hochgerner H, Petukhov V, Lidschreiber K,
625 Kastriti ME, Lonnerberg P, Furlan A, Fan J, Borm LE, Liu Z, van Bruggen D, Guo J, He
626 X, Barker R, Sundstrom E, Castelo-Branco G, Cramer P, Adameyko I, Linnarsson S,
627 Kharchenko PV. RNA velocity of single cells. *Nature* 2018; 560: 494-498.
- 628 16. Hager M, Cowland JB, Borregaard N. Neutrophil granules in health and disease. *J Intern*
629 *Med* 2010; 268: 25-34.
- 630 17. Borregaard N, Sorensen OE, Theilgaard-Monch K. Neutrophil granules: a library of innate
631 immunity proteins. *Trends Immunol* 2007; 28: 340-345.
- 632 18. Hauert AB, Martinelli S, Marone C, Niggli V. Differentiated HL-60 cells are a valid model
633 system for the analysis of human neutrophil migration and chemotaxis. *Int J Biochem*
634 *Cell Biol* 2002; 34: 838-854.
- 635 19. Jennings S, Ng HP, Wang G. Establishment of a DeltaF508-CF promyelocytic cell line for
636 cystic fibrosis research and drug screening. *J Cyst Fibros* 2019; 18: 44-53.
- 637 20. Schupp JC, Khanal S, Gomez JL, Sauler M, Adams TS, Chupp GL, Yan X, Poli S, Zhao Y,
638 Montgomery RR, Rosas IO, Dela Cruz CS, Bruscia EM, Egan ME, Kaminski N, Britto
639 CJ. Single-Cell Transcriptional Archetypes of Airway Inflammation in Cystic Fibrosis.
640 *Am J Respir Crit Care Med* 2020; 202: 1419-1429.
- 641 21. Shan SO. ATPase and GTPase Tangos Drive Intracellular Protein Transport. *Trends Biochem*
642 *Sci* 2016; 41: 1050-1060.
- 643 22. Adib-Conquy M, Pedron T, Petit-Bertron AF, Tabary O, Corvol H, Jacquot J, Clement A,
644 Cavaillon JM. Neutrophils in cystic fibrosis display a distinct gene expression pattern.
645 *Mol Med* 2008; 14: 36-44.
- 646 23. Margaroli C, Moncada-Giraldo D, Gulick DA, Dobosh B, Giacalone VD, Forrest OA, Sun F,
647 Gu C, Gaggar A, Kissick H, Wu R, Gibson G, Tirouvanziam R. Transcriptional firing
648 represses bactericidal activity in cystic fibrosis airway neutrophils. *Cell Rep Med* 2021; 2:
649 100239.
- 650 24. Sajjan U, Corey M, Humar A, Tullis E, Cutz E, Ackerley C, Forstner J. Immunolocalisation
651 of *Burkholderia cepacia* in the lungs of cystic fibrosis patients. *J Med Microbiol* 2001;
652 50: 535-546.
- 653 25. Hartl D, Latzin P, Hordijk P, Marcos V, Rudolph C, Woischnik M, Krauss-Etschmann S,
654 Koller B, Reinhardt D, Roscher AA, Roos D, Griese M. Cleavage of CXCR1 on
655 neutrophils disables bacterial killing in cystic fibrosis lung disease. *Nat Med* 2007; 13:
656 1423-1430.
- 657 26. Su X, Looney MR, Su HE, Lee JW, Song Y, Matthay MA. Role of CFTR expressed by
658 neutrophils in modulating acute lung inflammation and injury in mice. *Inflamm Res* 2011.
- 659 27. Witko-Sarsat V, Allen RC, Paulais M, Nguyen AT, Bessou G, Lenoir G, Descamps-Latscha
660 B. Disturbed myeloperoxidase-dependent activity of neutrophils in cystic fibrosis
661 homozygotes and heterozygotes, and its correction by amiloride. *J Immunol* 1996; 157:
662 2728-2735.
- 663 28. Painter RG, Valentine VG, Lanson NA, Jr., Leidal K, Zhang Q, Lombard G, Thompson C,
664 Viswanathan A, Nauseef WM, Wang G. CFTR Expression in human neutrophils and the
665 phagolysosomal chlorination defect in cystic fibrosis. *Biochemistry* 2006; 45: 10260-
666 10269.
- 667 29. Tirouvanziam R, Gernez Y, Conrad CK, Moss RB, Schrijver I, Dunn CE, Davies ZA,
668 Herzenberg LA. Profound functional and signaling changes in viable inflammatory

- 669 neutrophils homing to cystic fibrosis airways. *Proc Natl Acad Sci U S A* 2008; 105: 4335-
670 4339.
- 671 30. Reeves EP, Williamson M, O'Neill SJ, Grealley P, McElvaney NG. Nebulized hypertonic
672 saline decreases IL-8 in sputum of patients with cystic fibrosis. *Am J Respir Crit Care*
673 *Med* 2011; 183: 1517-1523.
- 674 31. Corvol H, Fitting C, Chadelat K, Jacquot J, Tabary O, Boule M, Cavaillon JM, Clement A.
675 Distinct cytokine production by lung and blood neutrophils from children with cystic
676 fibrosis. *Am J Physiol Lung Cell Mol Physiol* 2003; 284: L997-L1003.
- 677 32. Marcos V, Zhou Z, Yildirim AO, Bohla A, Hector A, Vitkov L, Wiedenbauer EM,
678 Krautgartner WD, Stoiber W, Belohradsky BH, Rieber N, Kormann M, Koller B,
679 Roscher A, Roos D, Griese M, Eickelberg O, Doring G, Mall MA, Hartl D. CXCR2
680 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic
681 fibrosis airway inflammation. *Nat Med* 2010; 16: 1018-1023.
- 682 33. Kettle AJ, Turner R, Gangell CL, Harwood DT, Khalilova IS, Chapman AL, Winterbourn
683 CC, Sly PD. Oxidation contributes to low glutathione in the airways of children with
684 cystic fibrosis. *Eur Respir J* 2014.
- 685 34. Moriceau S, Lenoir G, Witko-Sarsat V. In cystic fibrosis homozygotes and heterozygotes,
686 neutrophil apoptosis is delayed and modulated by diamide or roscovitine: evidence for an
687 innate neutrophil disturbance. *J Innate Immun* 2010; 2: 260-266.
- 688 35. Pohl K, Hayes E, Keenan J, Henry M, Meleady P, Molloy K, Jundi B, Bergin DA, McCarthy
689 C, McElvaney OJ, White MM, Clynes M, Reeves EP, McElvaney NG. A neutrophil
690 intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by
691 CFTR potentiator therapy. *Blood* 2014.
- 692 36. Petit-Bertron AF, Tabary O, Corvol H, Jacquot J, Clement A, Cavaillon JM, Adib-Conquy
693 M. Circulating and airway neutrophils in cystic fibrosis display different TLR expression
694 and responsiveness to interleukin-10. *Cytokine* 2008; 41: 54-60.
- 695 37. Ketelut-Carneiro N, Fitzgerald KA. Apoptosis, Pyroptosis, and Necroptosis-Oh My! The
696 Many Ways a Cell Can Die. *J Mol Biol* 2021: 167378.
- 697 38. Sheshachalam A, Srivastava N, Mitchell T, Lacy P, Eitzen G. Granule protein processing and
698 regulated secretion in neutrophils. *Frontiers in immunology* 2014; 5: 448.
- 699 39. Tucker SL, Sarr D, Rada B. Neutrophil extracellular traps are present in the airways of
700 ENaC-overexpressing mice with cystic fibrosis-like lung disease. *BMC Immunol* 2021;
701 22: 7.
- 702 40. Margaroli C, Garratt LW, Horati H, Dittrich AS, Rosenow T, Montgomery ST, Frey DL,
703 Brown MR, Schultz C, Guglani L, Kicic A, Peng L, Scholte BJ, Mall MA, Janssens HM,
704 Stick SM, Tirouvanziam R. Elastase Exocytosis by Airway Neutrophils Is Associated
705 with Early Lung Damage in Children with Cystic Fibrosis. *Am J Respir Crit Care Med*
706 2019; 199: 873-881.
- 707 41. Dittrich AS, Kuhbandner I, Gehrig S, Rickert-Zacharias V, Twigg M, Wege S, Taggart CC,
708 Herth F, Schultz C, Mall MA. Elastase activity on sputum neutrophils correlates with
709 severity of lung disease in cystic fibrosis. *Eur Respir J* 2018; 51.
- 710 42. Painter RG, Marrero L, Lombard GA, Valentine VG, Nauseef WM, Wang G. CFTR-
711 mediated halide transport in phagosomes of human neutrophils. *J Leukoc Biol* 2010; 87:
712 933-942.
- 713 43. Wang G. Chloride flux in phagocytes. *Immunol Rev* 2016; 273: 219-231.

- 714 44. Wang G, Nauseef WM. Salt, chloride, bleach, and innate host defense. *J Leukoc Biol* 2015;
715 98: 163-172.
- 716 45. Wang G, Nauseef WM. Neutrophil dysfunction in the pathogenesis of cystic fibrosis. *Blood*
717 2022; 139: 2622-2631.
- 718 46. Painter RG, Bonvillain RW, Valentine VG, Lombard GA, LaPlace SG, Nauseef WM, Wang
719 G. The role of chloride anion and CFTR in killing of *Pseudomonas aeruginosa* by normal
720 and CF neutrophils. *J Leukoc Biol* 2008; 83: 1345-1353.
- 721 47. Dickerhof N, Isles V, Pattemore P, Hampton MB, Kettle AJ. Exposure of *Pseudomonas*
722 *aeruginosa* to bactericidal hypochlorous acid during neutrophil phagocytosis is
723 compromised in cystic fibrosis. *J Biol Chem* 2019; 294: 13502-13514.
- 724 48. Ng HP, Jennings S, Wellem D, Sun F, Xu J, Nauseef WM, Wang G. Myeloid CFTR loss-of-
725 function causes persistent neutrophilic inflammation in cystic fibrosis. *J Leukoc Biol*
726 2020; 108: 1777-1785.
- 727 49. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, 3rd, Zheng S, Butler A, Lee MJ, Wilk AJ,
728 Darby C, Zager M, Hoffman P, Stoeckius M, Papalexi E, Mimitou EP, Jain J, Srivastava
729 A, Stuart T, Fleming LM, Yeung B, Rogers AJ, McElrath JM, Blish CA, Gottardo R,
730 Smibert P, Satija R. Integrated analysis of multimodal single-cell data. *Cell* 2021; 184:
731 3573-3587 e3529.
- 732 50. Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner HA, Trapnell C. Reversed graph
733 embedding resolves complex single-cell trajectories. *Nat Methods* 2017; 14: 979-982.
- 734 51. Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M,
735 Loh PR, Raychaudhuri S. Fast, sensitive and accurate integration of single-cell data with
736 Harmony. *Nat Methods* 2019; 16: 1289-1296.
- 737 52. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological
738 themes among gene clusters. *OMICS* 2012; 16: 284-287.
- 739 53. Bergen V, Lange M, Peidli S, Wolf FA, Theis FJ. Generalizing RNA velocity to transient
740 cell states through dynamical modeling. *Nat Biotechnol* 2020; 38: 1408-1414.
- 741 54. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular
742 Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst* 2015; 1: 417-425.
- 743 55. Aibar S, Gonzalez-Blas CB, Moerman T, Huynh-Thu VA, Imrichova H, Hulselmans G,
744 Rambow F, Marine JC, Geurts P, Aerts J, van den Oord J, Atak ZK, Wouters J, Aerts S.
745 SCENIC: single-cell regulatory network inference and clustering. *Nat Methods* 2017; 14:
746 1083-1086.
- 747 56. Corridoni D, Antanaviciute A, Gupta T, Fawcner-Corbett D, Aulicino A, Jagielowicz M,
748 Parikh K, Repapi E, Taylor S, Ishikawa D, Hatano R, Yamada T, Xin W, Slawinski H,
749 Bowden R, Napolitani G, Brain O, Morimoto C, Koohy H, Simmons A. Single-cell atlas
750 of colonic CD8(+) T cells in ulcerative colitis. *Nat Med* 2020; 26: 1480-1490.
- 751

752

FIGURE LEGENDS

753 **Fig. 1. Atlas and transcriptional signatures of peripheral blood neutrophils from CF**
754 **patients and healthy controls (HC).** **a**, UMAP of peripheral blood neutrophils from their basal
755 state and LPS-stimulated activating state. There are 4 groups of cells: 1) HC, colored in red, 2)
756 HC_LPS, colored in blue, 3) CF, colored in green, and 4) CF_LPS, colored in purple. **b**, UMAP
757 of neutrophils from HC and HC_LPS groups. **c**, UMAP of neutrophils from CF and CF_LPS
758 groups. **d**, Venn diagram showing similarities of DEGs among the 4 groups of neutrophils, **e**,
759 Heatmap showing the top 30 DEGs from each group. Selected immune related genes are marked.
760 **f**, Dotplot showing Gene Ontology (GO) enrichment of DEGs from 4 groups.

761

762 **Fig. 2. Gene scores for immune properties of CF and HC neutrophils at resting and upon**
763 **LPS stimulation.** **a-h**, Boxplots showing neutrophil immune scores of HC and CF neutrophils in
764 resting (– LPS) and LPS stimulated (+ LPS) conditions. **a**, Neutrophil activation score (GO:
765 0042119). **b**, Neutrophil chemotaxis score (GO: 0030593). **c**, Score for cytokine-mediated
766 signaling pathway (GO: 0019221). **d**, Score for neutrophil migration (GO: 1990266). **e**, Score for
767 immune response-regulating signaling pathway (GO: 0002764). **f**, Score for toll-like receptor
768 signaling pathway (GO: 0002224). **g**, Score for pattern recognition receptor signaling pathway
769 (GO: 0002221). **h**, Score for response to LPS (GO: 0032496). **i**, UMAP showing dataset
770 integration of our HC cohorts and selected Franco Lab HC cohorts. **j & k**, Box plots showing
771 two immune function scores in a 3-group comparison. **j**, Neutrophil activation score (GO:
772 0042119). **k**, Score for cytokine-mediated signaling pathway (GO: 0019221). ANOVA test was
773 used to judge statistical significance between two comparing groups. * $p < 0.05$, ** $p < 0.01$,

774 *** $p < 0.001$. Red asterisks indicate that CF neutrophils have significantly higher score and blue
775 asterisks significantly lower score in each comparison with HC counterparts.

776

777 **Fig. 3. Cell state transition of CF and HC neutrophils in response to LPS.** **a**, Monocle
778 trajectory of HC neutrophils colored by states (Basal, Activating and Aging). **b**, Monocle
779 trajectory of HC neutrophils colored by groups (HC and HC_LPS). **c**, UMAP of the neutrophils
780 from HC and HC_LPS groups, colored by states. **d**, GO enrichment of DEGs in each state of HC
781 neutrophils. **e**, Monocle trajectory of CF neutrophils, colored by states. **f**, Monocle trajectory of
782 CF neutrophils, colored by groups. **g**, UMAP of the neutrophils from HC and HC_LPS groups,
783 colored by states. **h**, Proportions of Activating state and Aging state in the population of
784 HC_LPS or CF_LPS cells. **i & j**, Venn diagrams showing overlapping DEGs between HC
785 neutrophils and CF neutrophils in the Activating state (**i**) or Aging state (**j**).

786

787 **Fig. 4. Cell fate decision and GO enrichment of CF and HC neutrophils in response to LPS.**
788 **a**, RNA velocity plot revealing the origin and inter-relationship of 3 states of HC neutrophils. **b**,
789 UMAP-embedding root cells and end point of HC neutrophils. **c**, RNA velocity plot showing the
790 origin and inter-relationship of 3 states of CF neutrophils. **d**, UMAP-embedding root cell and end
791 point of CF neutrophils. **e**, Heatmap showing upregulated genes (red) and downregulated genes
792 (blue) in CF samples in Activating state or Aging state, as compared to HC. **f-h**, Comparisons of
793 neutrophil property and function scores between HC and CF neutrophils in Activating state or
794 Aging state. **f**, Neutrophil activation scores; **g**, Differentiation and aging scores; **h**, Granule

795 formation scores. Significance was determined by two-way ANOVA. * $p < 0.05$, ** $p < 0.01$,
796 *** $p < 0.001$. Red asterisks indicate that CF neutrophils have significantly higher scores, and blue
797 asterisks significantly lower scores, as compared to HC neutrophils.

798

799 **Fig. 5. Pre-activation of neutrophils derived from CF HL-60 cells. a.** UMAP of
800 WT_differentiated HL-60 cells (WT_dHL-60). **b.** UMAP of CF_differentiated HL-60 cells
801 (CF_dHL-60). **c.** Dot plot showing GO enrichment of DEGs in 4 groups. **d-k,** Box plots showing
802 activation scores of neutrophils derived from WT and CF HL-60 cells with or without LPS
803 stimulation. The significance was determined by two-way ANOVA. * $p < 0.05$, ** $p < 0.01$,
804 *** $p < 0.001$. Red asterisks indicate that the derived CF neutrophils have significantly higher
805 scores, and blue asterisks significantly lower scores, as compared to the derived WT neutrophils.

806

807 **Fig. 6. Gene reprogramming in CF sputum neutrophils as compared to CF blood**
808 **neutrophils. a,** UMAP of 3 groups of CF PMN: 1) CF blood PMN in their native state, 2) CF
809 blood PMN stimulated with LPS, and 3) CF sputum PMN. **b,** Heat map showing the top 20
810 DEGs from each group of CF neutrophils. Selected immune-related genes are marked. **c,** GO
811 enrichment comparisons of DEGs among the 3 group of CF neutrophils. **d,** KEGG analysis of
812 DEGs from each group of CF neutrophils.

813

814 **Fig. 7. Comparisons of immune-related properties between CF blood neutrophils and CF**
815 **sputum neutrophils. a-d**, Comparisons of neutrophil property and function scores among CF
816 blood PMN, CF blood PNM_LPS, and CF sputum PMN. **a**, Differentiation and aging scores; **b**,
817 Granule formation scores; **c**, Neutrophil activation scores; **d**, Inflammation scores. Significance
818 was determined by one-way ANOVA. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. Red asterisks indicate
819 that the latter group has significantly higher scores, and blue asterisks significantly lower scores,
820 as compared to the former group in each comparison. Gray lines in each violin plot represent
821 median.


822

823


824

825 **Figure 1**


826
827
828
829
830



831 **Figure 2**




832 **Figure 3**




833

834 **Figure 4**
835




836 **Figure 5**



837

838 **Figure 6**

839



840 **Figure 7**

841

